Eli Lilly Jumps, Comcast Gains, Meta Falls

On this episode of Stock Movers:
- Eli Lilly (LLY) raised its full-year guidance as revenue from its weight loss and diabetes drugs beat expectations in the third quarter. The company's diabetes drug Mounjaro and obesity treatment Zepbound outpaced expectations by a combined nearly $1.3 billion, with the vast majority of the beat coming from the diabetes drug. Lilly now expects full-year sales of $63 billion to $63.5 billion and adjusted earnings per share of $23 to $23.70, after sales in the third quarter were $17.6 billion, exceeding the average Wall Street estimate.
- Comcast (CMCSA) lost 104,000 net broadband subscribers in the third quarter, fewer than the loss of 140,000 predicted by analysts. The company reported a net loss of 257,000 video subscribers, beating expectations for 321,000 customer departures. Third-quarter revenue fell 2.7% to $31.2 billion, beating estimates of $30.7 billion.
- Meta Platforms (META) aims to sell at least $25 billion of investment-grade bonds on Thursday, according to people familiar with the matter. The company is looking to issue notes in as many as six parts, ranging from five to 40 years in length, with proceeds set to go toward general corporate purposes. Meta is infusing artificial intelligence services into its key products and needs to invest billions of dollars in data centers and other key infrastructure to fuel those offerings.

See omnystudio.com/listener for privacy information.